Clinical Context
Lobar pneumonia is classically caused by Streptococcus pneumoniae and presents with acute onset, high fever, and consolidation in a single lobe. The patient's rusty sputum and positive blood culture confirm pneumococcal lobar pneumonia.
Drug of Choice
Key Point
Ceftriaxone (third-generation cephalosporin) is the first-line agent for community-acquired lobar pneumonia caused by S. pneumoniae, especially when bacteremia is present.
Why Ceftriaxone?
- 1.
Excellent lung penetration — achieves high concentrations in lung tissue and pleural fluid
- 2.
Broad spectrum — covers S. pneumoniae, H. influenzae, and gram-negative organisms
- 3.
Bactericidal — superior to macrolides for invasive pneumococcal disease
- 4.
Guideline standard — recommended by IDSA and Indian chest society guidelines for CAP with bacteremia
Comparison with Other Options
| Agent | Use Case | Limitation |
|---|
| Amoxicillin-clavulanate | Oral step-down after IV therapy; mild CAP | Inadequate for bacteremic pneumonia; poor lung penetration |
| Ceftriaxone | First-line IV for lobar pneumonia with bacteremia | None for this indication |
| Fluoroquinolone (levofloxacin) | Atypical organisms; alternative if allergy | Not preferred for invasive pneumococcal disease |
| Azithromycin | Atypical coverage only; adjunctive | Monotherapy inadequate for pneumococcal lobar pneumonia |
High-Yield Distinction
High-YieldNEET PG
Lobar pneumonia (acute onset, single lobe, bacteremia) → Cephalosporin (ceftriaxone). Bronchopneumonia (insidious, patchy, elderly/debilitated) → broader coverage depending on organism.
Clinical Pearl
Clinical Pearl
In a patient with positive blood culture and lobar consolidation, ceftriaxone should be initiated empirically without waiting for sensitivities, as it covers the most likely pathogen (S. pneumoniae) and has excellent bactericidal activity.
